Covidien plc Announces Final Results From Landmark DEFINITIVE LE Study in Patients With Peripheral Arterial Disease
LAS VEGAS--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced final 12-month results from its DEFINITIVE LE (Determination of Effectiveness of SilverHawk™ / TurboHawk™ Peripheral Plaque Excision Systems for the Treatment of Infrainguinal Vessels/Lower Extremities) study.